Bousset, Luc

α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 1,130

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats

Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 925

Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes

Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L., Olivo‐Marin, J., Melki, R., & Zurzolo, C. (2016) · The EMBO Journal

Parkinson's Disease Mechanisms and TreatmentsCellular transport and secretion

Cited by 414

Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes

Scheiblich, H., Dansokho, C., Mercan, D., Schmidt, S. V., Bousset, L., Wischhof, L., Eikens, F., Odainic, A., Spitzer, J., Griep, A., et al. (2021) · Cell

Neuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

Cited by 360

Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies

Tardivel, M., Bégard, S., Bousset, L., Dujardin, S., Coens, A., Melki, R., Buée, L., & Colin, M. (2016) · Acta Neuropathologica Communications

Alzheimer's disease research and treatmentsExtracellular vesicles in disease

Cited by 305

The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies

Van der Perren, A., Gelders, G., Fenyi, A., Bousset, L., Brito, F., Peelaerts, W., Van den Haute, C., Gentleman, S., Melki, R., & Baekelandt, V. (2020) · Acta Neuropathologica

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 277

Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease

Grozdanov, V., Bousset, L., Hoffmeister, M., Bliederhaeuser, C., Meier, C., Madiona, K., Pieri, L., Kiechle, M., McLean, P. J., Kassubek, J., et al. (2019) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 161

Microglial NLRP3 Inflammasome Activation Upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies

Scheiblich, H., Bousset, L., Schwartz, S., Griep, A., Latz, E., Melki, R., & Heneka, M. T. (2021) · The Journal of Immunology

Neuroinflammation and Neurodegeneration MechanismsInflammasome and immune disorders

Cited by 122

Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons

Kawahata, I., Bousset, L., Melki, R., & Fukunaga, K. (2019) · International Journal of Molecular Sciences

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 56

An Efficient Procedure for Removal and Inactivation of Alpha-Synuclein Assemblies from Laboratory Materials

Bousset, L., Brundin, P., Böckmann, A., Meier, B., & Melki, R. (2016) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsPrion Diseases and Protein Misfolding

Cited by 53